COVID-19 | Treatments

 Healthcare providers should advise patients on strategies to ensure medication adherence and continuity. Plans should be in place and ample supplies should be available to address any potential shortages or needs for rescue therapies.

If feasible, providers might consider writing 90-day rather than 30-day supplies of medications. 

COVID-19 Vaccine Information

• Epilepsy and COVID 2021
• AES Statement for Health Care Providers on COVID-19 Vaccination for People with Epilepsy [PDF], August 31, 2021
• AES Compilation of Resources on COVID-19 Vaccine Prioritization [PDF], December 23, 2020
• Should patients with epilepsy be vaccinated against coronavirus disease 2019? A Systematic Review and Meta-Analysis

Antiseizure Medications (ASMs)

• AES FDA News and Drug Alerts
• FDA Drug Shortages web page 
• American Society of Health-System Pharmacists (ASHP) drug shortage tracking system which can now be integrated into EHR systems
• A Summary of Antiseizure Medications Available in the United States: 2020 Update, Tabular PDF summary of the most commonly used ASMs available for prescription in the United States. Updates and replaces the 2018 version.
• Substitution of different formulations of antiepileptic drugs for the treatment of epilepsy; a 2016 AES Position Statement

Managing Medications

• AES Clinical Corner: Paxlovid™, AES, February 25, 2022
• Paxlovid™ Information from FDA and Guidance for AES Members, AES, February 1, 2022
• Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations, AES, April 9, 2020
• Effective Engagement of Pharmacists During COVID-19 and Beyond, AES, April 9, 2020
  
• AES Comments on Therapeutic Substitution of Medications, April 3, 2020 [PDF]
  
• FDA updates on a range of COVID-related Center for Drug Evaluation and Research Resources
• Not your usual drug-drug interactions: Monoclonal antibody-based therapeutics may interact with antiseizure medications